JP2024516818A5 - - Google Patents

Info

Publication number
JP2024516818A5
JP2024516818A5 JP2023565954A JP2023565954A JP2024516818A5 JP 2024516818 A5 JP2024516818 A5 JP 2024516818A5 JP 2023565954 A JP2023565954 A JP 2023565954A JP 2023565954 A JP2023565954 A JP 2023565954A JP 2024516818 A5 JP2024516818 A5 JP 2024516818A5
Authority
JP
Japan
Prior art keywords
cancer
amino acid
acid sequence
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023565954A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516818A (ja
Filing date
Publication date
Priority claimed from PCT/CA2021/050572 external-priority patent/WO2022226623A1/en
Application filed filed Critical
Publication of JP2024516818A publication Critical patent/JP2024516818A/ja
Publication of JP2024516818A5 publication Critical patent/JP2024516818A5/ja
Pending legal-status Critical Current

Links

JP2023565954A 2021-04-27 2022-04-26 腫瘍への免疫細胞浸潤を可能にするための方法 Pending JP2024516818A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CA2021/050572 WO2022226623A1 (en) 2021-04-27 2021-04-27 Method for allowing immune cells infiltration in tumors
CAPCT/CA2021/050572 2021-04-27
PCT/CA2022/050632 WO2022226637A1 (en) 2021-04-27 2022-04-26 Method for allowing immune cells infiltration in tumors

Publications (2)

Publication Number Publication Date
JP2024516818A JP2024516818A (ja) 2024-04-17
JP2024516818A5 true JP2024516818A5 (https=) 2025-05-08

Family

ID=83846453

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023566662A Pending JP2024516416A (ja) 2021-04-27 2021-04-27 腫瘍への免疫細胞浸潤を可能にするための方法
JP2023565954A Pending JP2024516818A (ja) 2021-04-27 2022-04-26 腫瘍への免疫細胞浸潤を可能にするための方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2023566662A Pending JP2024516416A (ja) 2021-04-27 2021-04-27 腫瘍への免疫細胞浸潤を可能にするための方法

Country Status (10)

Country Link
US (2) US20240199758A1 (https=)
EP (2) EP4329801A4 (https=)
JP (2) JP2024516416A (https=)
KR (2) KR20240014052A (https=)
CN (2) CN117479955A (https=)
AU (2) AU2021442702A1 (https=)
CA (2) CA3173786A1 (https=)
IL (2) IL307954A (https=)
MX (2) MX2023012766A (https=)
WO (2) WO2022226623A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3173786A1 (en) * 2021-04-27 2022-10-27 Mario Filion Method for allowing immune cells infiltration in tumors
MX2024009671A (es) * 2022-02-07 2024-08-19 Alethia Biotherapeutics Inc Terapia de combinación para uso en el tratamiento del cáncer de pulmón de células no pequeñas.
CN118914553B (zh) * 2024-07-22 2025-03-18 西安医学院第一附属医院 一种结直肠腺瘤和结直肠癌早期筛查的生物标志物的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1882A (en) 1872-12-11 Angus. Campbell A towel hanger
ES2543341T3 (es) 2005-09-13 2015-08-18 National Research Council Of Canada Métodos y composiciones para modular la actividad de células tumorales
EA034462B1 (ru) 2009-11-24 2020-02-11 Алетиа Байотерапьютикс Инк. Антикластериновые антитела и антигенсвязывающие фрагменты и их использование для уменьшения объема новообразований
US9822170B2 (en) * 2012-02-22 2017-11-21 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer
CA3173786A1 (en) * 2021-04-27 2022-10-27 Mario Filion Method for allowing immune cells infiltration in tumors

Similar Documents

Publication Publication Date Title
Tarantino et al. Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
JP2024516818A5 (https=)
Singh et al. TNBC: potential targeting of multiple receptors for a therapeutic breakthrough, nanomedicine, and immunotherapy
Lee Chemotherapy for lung cancer in the era of personalized medicine
Zhang et al. Systemic treatment of advanced or recurrent biliary tract cancer
Oronsky et al. What's new in SCLC? A review
Herreros-Villanueva et al. Adjuvant and neoadjuvant treatment in pancreatic cancer
Satoh et al. Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer
JP2021169479A5 (https=)
IL294800A (en) Methods for treatment of cancer with an anti-tigit antagonist antibody
Harada et al. Global chemotherapy development for gastric cancer
ES2656168T3 (es) Anticuerpo anti cadherina marcado con un metal radioactivo
Aoki et al. Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective
Rebelo et al. Pancreatic cancer therapy review: from classic therapeutic agents to modern nanotechnologies
Davidson et al. Current and future therapies for advanced gastric cancer
RU2010151602A (ru) Комбинированная терапия с помощью рм00104 и другого противоопухолевого средства
JP2011520921A5 (https=)
Yusoh et al. Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies
Mosquera et al. Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials
JP2021511372A5 (https=)
JP2021502334A5 (https=)
JP2024545427A5 (https=)
Lu et al. Exploring the therapeutic potential of ADC combination for triple-negative breast cancer
Roviello et al. Maintenance in gastric cancer: New life for an old issue?
Saltos et al. Breaking the impasse: advances in treatment of small cell lung cancer